Programmed death as a therapeutic target to reduce myocardial infarction

Trends in Pharmacological Sciences

Volumn 28, Issue 9, 2007, Pages 492-499

  Webster, Keith A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BH3 PROTEIN; CALCIUM CHANNEL; CYCLOSPORIN A; DESFLURANE; GLYCOGEN SYNTHASE KINASE 3BETA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INHALATION ANESTHETIC AGENT; INTRAVENOUS ANESTHETIC AGENT; MAMMALIAN TARGET OF RAPAMYCIN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OPIATE; P53 MODULATED UPREGULATOR OF APOPTOSIS PROTEIN; PHOSPHODIESTERASE V INHIBITOR; PROPOFOL; PROTEIN; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; PROTEIN BNIP3; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; SILDENAFIL; TADALAFIL; TRANSCRIPTION FACTOR FOXO; TROPONIN I; UNCLASSIFIED DRUG; VARDENAFIL;

APOPTOSIS; CELL DEATH; CORONARY ARTERY BYPASS GRAFT; DNA DAMAGE; DRUG EFFICACY; DRUG SAFETY; ERECTILE DYSFUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MITOCHONDRION; HEART MUSCLE CELL; HUMAN; INHALATION ANESTHESIA; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; NONHUMAN; OFF PUMP CORONARY SURGERY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; APOPTOSIS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL INFARCTION; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 34548402079     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.07.004     Document Type: Review

References (63)

1. Webster K.A., et al. Redox stress and the contributions of BH3-only proteins to infarction. Antioxid. Redox Signal. 8 (2006) 1667-1676
2. Willis S.N., and Adams J.M. Life in the balance: how BH3-only proteins induce apoptosis. Curr. Opin. Cell Biol. 17 (2005) 617-625
3. Danial N.N., and Korsmeyer S.J. Cell death: critical control points. Cell 116 (2004) 205-219
4. Tsujimoto Y., et al. Mitochondrial membrane permeability transition and cell death. Biochim. Biophys. Acta 1757 (2006) 1297-1300
5. Dejean L.M., et al. 2006 Is MAC the knife that cuts cytochrome c from mitochondria during apoptosis?. Cell Death Differ. 13 (2006) 1387-1395
6. Nutt L.K., et al. Bax and Bak promote apoptosis by modulating endoplasmic reticular and mitochondrial Ca2+ stores. J. Biol. Chem. 277 (2002) 9219-9225
7. Nakagawa T., et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434 (2005) 652-658
8. Baines C.P., et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434 (2005) 658-662
9. Kerr P.M., et al. Reversal of permeability transition during recovery of hearts from ischemia and its enhancement by pyruvate. Am. J. Physiol. 276 (1999) H496-H502
10. Kokoszka J.E., et al. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 427 (2004) 461-465
11. Baines C.P., et al. 2007 Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nat. Cell Biol. 9 (2007) 550-555
12. Halestrap A.P. Calcium, mitochondria and reperfusion injury: a pore way to die. Biochem. Soc. Trans. 34 (2006) 232-237
13. Bott-Flugel L., et al. Gene transfer of the pancaspase inhibitor P35 reduces myocardial infarct size and improves cardiac function. J. Mol. Med. 83 (2005) 526-534
14. Hochhauser E., et al. Bax ablation protects against myocardial ischemia reperfusion injury in transgenic mice. Am. J. Physiol. Heart Circ. Physiol. 284 (2003) H2351-H2359
15. Downey J.M., and Cohen M.V. Reducing infarct size in the setting of acute myocardial infarction. Prog. Cardiovasc. Dis. 48 (2006) 363-371
16. Hofstra L., et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 356 (2000) 209-212
17. Downey J.M., and Cohen M.V. Unraveling the mysteries of classical preconditioning. J. Mol. Cell. Cardiol. 39 (2005) 845-848
18. Jones S.P., and Bolli R. The ubiquitous role of nitric oxide in cardioprotection. J. Mol. Cell. Cardiol. 40 (2006) 16-23
19. Staat P., et al. Postconditioning the human heart. Circulation 112 (2005) 2143-2148
20. Juhaszova M., et al. Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J. Clin. Invest. 113 (2004) 1535-1549
21. Efthymiou C.A., et al. Atorvastatin and myocardial reperfusion injury: new pleiotropic effect implicating multiple prosurvival signaling. J. Cardiovasc. Pharmacol. 45 (2005) 247-252
22. Pan W., et al. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation 110 Suppl 1 (2004) II45-II49
23. Jones S.P., et al. Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circ. Res. 93 (2003) 697-699
24. Kukreja R.C., et al. Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications. Vascul. Pharmacol. 42 (2005) 219-232
25. Opie L.H., et al. Controversies in ventricular remodeling. Lancet 367 (2006) 356-367
26. Takimoto E., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat. Med. 11 (2005) 214-222
27. Rosanio S., et al. Enhanced cardioprotection against ischemia reperfusion injury with combining sildenafil with low-dose atorvastatin. Cardiovasc. Drugs Ther. 20 (2006) 27-36
28. Fung E., et al. The potential use of type-5 phosphodiesterase inhibitors in coronary artery bypass graft surgery. Chest 128 (2005) 3065-3073
29. De Hert S.G. Volatile anesthetics and cardiac function. Semin. Cardiothorac. Vasc. Anesth. 10 (2006) 33-42
30. Raphael J., et al. Isoflurane-induced myocardial preconditioning is dependent on phosphatidylinositol-3-kinase/Akt signalling. Br. J. Anaesth. 95 (2005) 756-763
31. Bienengraeber M.W., et al. Cardioprotection by volatile anesthetics. Vascul. Pharmacol. 42 (2005) 243-252
32. Kevin L.G., et al. Reactive oxygen species as mediators of cardiac injury and protection: the relevance to anesthesia practice. Anesth. Analg. 101 (2005) 1275-1287
33. De Hert S.G. Cardioprotection with volatile anesthetics: clinical relevance. Curr. Opin. Anaesthesiol. 17 (2004) 57-62
34. Guarracino F., et al. Myocardial damage prevented by volatile anesthetics: a multicenter randomized controlled study. J. Cardiothorac. Vasc. Anesth. 20 (2006) 477-483
35. De Hert S.G. Anesthetic preconditioning: how important is it in today's cardiac anesthesia?. J. Cardiothorac. Vasc. Anesth. 20 (2006) 473-476
36. Li Q., et al. Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences. Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H584-H589
37. Smith Jr. R.S., et al. Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction. Life Sci. 76 (2005) 2457-2471
38. Webster K.A. Therapeutic angiogenesis: a complex problem requiring a sophisticated approach. Cardiovasc. Toxicol. 3 (2003) 283-298
39. Duranski M.R., et al. Cytoprotective effects of nitrite during in vivo ischemia reperfusion of the heart and liver. J. Clin. Invest. 115 (2005) 1232-1240
40. Juhaszova M., et al. Protection in the aged heart: preventing the heart-break of old age?. Cardiovasc. Res. 66 (2005) 233-244
41. Tsang A., et al. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes 54 (2005) 2360-2364
42. Inagaki K., et al. Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo. Circulation 108 (2003) 2304-2307
43. Murriel C.L., et al. Protein kinase Cdelta activation induces apoptosis in response to cardiac ischemia and reperfusion damage: a mechanism involving BAD and the mitochondria. J. Biol. Chem. 279 (2004) 47985-47991
44. Regula K.M., et al. Inducible expression of BNIP3 provokes mitochondrial defects and hypoxia-mediated cell death of ventricular myocytes. Circ. Res. 91 (2002) 226-231
45. Vande Velde C., et al. BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore. Mol. Cell. Biol. 20 (2000) 5454-5468
46. Adams J.M., and Cory S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem. Sci. 26 (2001) 61-66
47. Degli Esposti M., and Dive C. Mitochondrial membrane permeabilisation by Bax/Bak. Biochem. Biophys. Res. Commun. 304 (2003) 455-461
48. Antignani A., and Youle R.J. How do Bax and Bak lead to permeabilization of the outer mitochondrial membrane?. Curr. Opin. Cell Biol. 18 (2006) 685-689
49. Espost M.D. The roles of Bid. Apoptosis 7 (2002) 433-440
50. Scorrano L., et al. A distinct pathway remodels mitochondrial cristae and mobilizes cytochrome c during apoptosis. Dev. Cell 2 (2002) 55-67
51. Dejean L.M., et al. Oligomeric Bax is a component of the putative cytochrome c release channel MAC, mitochondrial apoptosis-induced channel. Mol. Biol. Cell 16 (2005) 2424-2432
52. Plesnila N., et al. BID mediates neuronal cell death after oxygen/glucose deprivation and focal cerebral ischemia. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 15318-15323
53. Chen M., et al. Calpain and mitochondria in ischemia/reperfusion injury. J. Biol. Chem. 277 (2002) 29282-29286
54. Takahashi M., et al. Possible involvement of calpain activation in pathogenesis of chronic heart failure after acute myocardial infarction. J. Cardiovasc. Pharmacol. 47 (2006) 413-421
55. Saez M.E., et al. The therapeutic potential of the calpain family: new aspects. Drug Discov. Today 11 (2006) 917-923
56. Webster K.A., et al. BNip3 and signal-specific programmed death in the heart. J. Mol. Cell. Cardiol. 38 (2005) 35-45
57. Ray R., et al. BNIP3 heterodimerizes with Bcl-2/Bcl-X(L) and induces cell death independent of a Bcl-2 homology 3 (BH3) domain at both mitochondrial and nonmitochondrial sites. J. Biol. Chem. 275 (2000) 1439-1448
58. Kubasiak L.A., et al. Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 12825-12830
59. Hamacher-Brady A., et al. Response to myocardial ischemia/reperfusion injury involves Bnip3 and autophagy. Cell Death Differ. 14 (2007) 146-157
60. Graham et al (2007) Regulation of Bnip3 death pathways by calcium, phosphorylation and hypoxia-reoxygenation. Jul 13; [Epub ahead of print]
61. Erlacher M., et al. BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood 106 (2005) 4131-4138
62. Reimertz C., et al. Gene expression during ER stress-induced apoptosis in neurons: induction of the BH3-only protein Bbc3/PUMA and activation of the mitochondrial apoptosis pathway. J. Cell Biol. 162 (2003) 587-597
63. Toth A., et al. Targeted deletion of Puma attenuates cardiomyocyte death and improves cardiac function during ischemia/reperfusion. Am. J. Physiol. Heart Circ. Physiol. 291 (2006) H52-H60